© 2019 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.
Such generic drugs could save nations huge sums in the coming years.
Their aim is to help remove existing barriers to the production and distribution of generic HCV treatment around the world.
Lawyers argue that the formula for sofosbuvir was based on “old science” and that the patent should be rejected.
Battle lines are drawn as the global health community prepares to face off with Big Pharma over the astronomic cost of treatment.
Gilead Sciences has expanded its global access program for HBV in developing countries by joining medicines patent pool.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.
